VolitionRx (NYSE-A:VNRX) Limited said it has appointed veteran marketing executive Mickie Henshall to its board of directors.
The company noted that Henshall has over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries. She currently serves as chief marketing officer at REALM IDx Inc, an integrated diagnostics company.
Volition said it has also appointed Henshall as a member of its compensation committee and the nominations and governance committee.
"We're delighted to have attracted someone of Mickie's caliber to Volition's board. Mickie's global marketing skill set and expertise, within the life sciences sector, will be vital to us as we progress towards full commercialization and bring our transformational Nucleosomics technology to market,” Volition executive chairman Martin Faulkes said in a statement.
READ: VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization efforts
Henshall told shareholders that she believes there is enormous potential for Volition to revolutionize the diagnosis of life-altering diseases through its Nu.Q product portfolio.
"I'm joining Volition at a significant stage in the company's development with the Nu.Q Vet test recently licensed to Heska, an industry leader, and Nu.Q NETs achieving CE marking,” Henshall said. “I look forward to supporting the board and senior leadership team in realizing Volition's mission.”
Henderson, Nevada-based Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas